S50 Posters / Growth Hormone & IGF Research 22S1 (2014) S25–S52

analysis with height increment (cm/month) at 0 .4-1 .5 years as dependent variable, the addition of IGF-I at 0 .7 years (ß=0 .36, P < 0 .05) to target height SDS (ß=0 .50, P<0 .01), birth weight SDS and gestational age, increased the R2 from 22% to 33% (P < 0 .002) .Conclusion: Higher IGF-I and lower IGBP-1 at PMA 30-37 weeks reflect increased growth increment during this period . Height increment at 0 .4-1 .5 years correlated independently with both target height SDS and IGF-I levels during this period suggesting receptor/postreceptor differences in preterms with different target height SDS .

PO4-3Serum levels of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3) in women with cervical cancer

D .H . Cho, M .S . Kim . Chonbuk National University Medical School, Jeonju-si, Korea, Republic of

Background: The aim of this study was to investigate the hypoth-esis that serum IGF-I and IGFBP-3 levels are related with cervical cancer and precancerous lesion .Methods: We included 104 women with cervical cancer and precancerous lesion without any treatment . They were classi-fied into followings according to pap smear test results: control, low-grade squamous intraepithelial lesion (LSIL) and high-grade squamous intraepithelial lesion (HSIL) . Subjects were classified into followings according to final diagnosis based on LEEP biopsy: control, CIN and cancer group . We performed anthropometric measurement and laboratory tests including pap smear result, HPV titer, ES, CRP, SCC, IGF-I and IGFBP-3 in all subjects .Results:1) In pap smear test, serum IGF-I and IGFBP-3 levels showed

no significant differences among 3 groups . But significantly lower value of serum IGF-I/IGFBP-3 molar ratio was found in LSIL or HSIL compared to controls . There was no significant difference in age, SCC, HPV titer, ESR and CRP among 3 groups .

2) In final diagnosis, IGF-I, IGFBP-3, molar ratio, age, SCC, HPV titer, ESR and CRP were not significantly different among 3 groups .

3) Serum IGFBP-3 had positive correlation with serum IGF-I and negative correlation with age and SCC . By final diagnosis, in CIN group, there was the same correlation mentioned above but in control group, IGFBP-3 had positive correlation only with IGF-I . In cancer group, IGFBP-3 was no correlated with IGF-I .

4) Serum IGFBP-3 had no correlation with HPV titer, ESR and CRP .Conclusion: Serum IGF-I/IGFBP-3 molar ratio level significantly decreased in LSIL or HSIL group compared to controls . In CIN group, IGFBP-3 was significantly associated with IGF-I, age and SCC but in cancer group, there was no relationship between IGFBP-3 and IGF-I, age, and SCC . These findings suggest that the progression to cervical cancer is associated with alteration in the IGF-I/IGFBP-3 system . But More studies are needed .

PO4-4Cerebrospinal fluid and serum levels of growth hormone (GH), insulin-like-growth factor-I (IGF-1), insulin-like growth factor binding protein -3 (IGFBP-3) and ghrelin in patients with bacterial and tuberculous meningitis

A . Akinci1, S . Gungor2, G . Yucel1, S . Gungor2, H .I . Ozerol3 . 1Pediatric Endocrinology, Inonu University Medical Faculty, Malatya, Turkey, 2Pediatric Neurology, Inonu University Medical Faculty, Malatya, Turkey, 3Clinical Microbiology, Inonu University Medical Faculty, Malatya, Turkey

Introduction: The somatotropic hormone levels change in acute and prolonged critical illnesses such as tuberculous meningitis (TbM) . This study aimed to determine the cerebrospinal fluid

(CSF) and serum levels of growth hormone (GH), insulinlike growth factor 1 (IGF-1), insulinlike growth factor-binding protein 3 (IGFBP-3), and ghrelin in patients with TbM and to compare the results with those of the patients with bacterial meningitis (BM) and of healthy controls .Methods: Nine patients with TbM and 14 patients with BM between the ages of 7 and 12 years were enrolled in this study . The control group was composed of 14 patients with no central nervous system infections . Growth hormone, IGF-1, and IGFBP-3 levels in serum and CSF were measured by enzyme-linked immunosorbent assay, and ghrelin levels were measured by radioimmunoassay .Results: Growth hormone and IGF-1 levels in serum and CSF were significantly lower in the TbM group than in the BM and control groups (P<0 .05) . Insulinlike growth factor-binding protein 3 levels were lower in the TbM and BM groups than in the control group (P<0 .05) . Ghrelin level in the TbM group was significantly higher than in the BM and control groups (P<0 .05) .Conclusions: Levels of growth factors such as GH and IGF-1 were lower in TbM than in other central nervous system infections . These data suggest that IGF-1, which is known to have a neuro-protective effect, may be the cause of neuronal loss and cerebral atrophy in TbM .

PO4-5Insulin like growth factor-1 therapy in five patients with growth hormone insensitivity

B . Ersoy, B . Ozhan, D . Kızılay, S . Kiremitci . Celal Bayar University, Manisa, Turkey

Introduction: Growth hormone insensitivity syndrome (GHIS), a genetic disease characterized by growth retardation combined with high serum concentration of growth hormone (GH) and low insulin-like growth factor 1 (IGF-1) levels, can be caused by mutations in the GH receptor (GHR) gene . In here, we reported the results of recombinant human insulin like growth factor-1 (rhIGF-1) therapy in 5 patients with GHI .Cases: All patients had high basal growth hormone levels, low IGF-1 and insulin like growth factor binding protein -3 (IGFBP-3) levels . All patients had a blunted IGF-I response to recombinant human GH . First patient with severely growth retardation from birth, had height standard deviation score (SDS) of -7 .42 at the age of 6 years . Second patient with mildly growth retardation from birth, had height SDS -7 .2 at the age of 2 .5 years . Height SDS of third, fourth and fifth patients were -2 .35 at the age of 1 year, -9 .84 at the age of 6 years, and -5 .2 at the age of 4 .5 years, respectively . Birth weights of last three patients were within nor-mal range . Recombinant IGF-I therapy (mecasermin, Increlex®, twice daily) initiated to the patients at different ages . Although the patients received IGF-1 therapy for 4 years irregularly, growth velocity has increased compared to before treatment (4-8 cm/year) . However, height SDS did not improve with therapy .Conclusion: Treatment with rhIGF-I stimulates linear growth in children with severe IGF-I deficiency due to GH insensitivity . IGF-1 therapy should be used regularly .

PO4-6Serum levels of IGF-I and IGFBP-1 in Indian diabetic population

M . Tekle1,2, S . Vasan1, K . Brismar1 . 1Karolinska University Hospital, Stockholm, Sweden, 2Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden

Lifestyle habits like diet, physical activities and alcohol consump-tion are important determinants of health and are linked to the prevalence of different pathological conditions such as diabetes .